Expertise in
1
conditions

Martin M. Eatock

Lisburn Road, 
Belfast, NIR, GB 
Expertise in
1
conditions
Lisburn Road, 
Belfast, NIR, GB 

Overview

Martin Eatock practices practicing medicine in Belfast, United Kingdom.

Mr. Eatock is highly rated in 1 condition, according to our data. His clinical expertise encompasses Pancreatic Islet Cell Tumor, Pancreatic Cancer, Cerebral Hypoxia, and Embryonal Tumor with Multilayered Rosettes.

He is actively involved in clinical research, co-authoring 21 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Lisburn Road, Belfast, NIR, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cisplatin, 5-fluorouracil or Capecitabine, Trastuzumab, Pertuzumab
Study Phase: Phase 2
A Prospective, Phase II, Double Blinded, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Vandetanib Therapy With Gemcitabine Therapy Alone in Locally Advanced or Metastatic Pancreatic Carcinoma
A Prospective, Phase II, Double Blinded, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Vandetanib Therapy With Gemcitabine Therapy Alone in Locally Advanced or Metastatic Pancreatic Carcinoma
Enrollment Status: Completed
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Caprelsa (Vandetanib)
Study Phase: Phase 2
View 1 Less Clinical Trial

21 Total Publications

Results of a modified Delphi consensus on the optimal testing pathway for oesophago-gastric cancer care in the UK.
Results of a modified Delphi consensus on the optimal testing pathway for oesophago-gastric cancer care in the UK.
Journal: BMJ open
Published: February 06, 2025

Frequently Asked Questions about Martin M. Eatock

Is Martin M. Eatock a top-rated expert for Pancreatic Islet Cell Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Martin M. Eatock is classified as an Advanced expert for Pancreatic Islet Cell Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Martin M. Eatock participate in research or clinical trials?

Yes. Martin M. Eatock has published 21 articles and abstracts on conditions like Pancreatic Islet Cell Tumor. You can view a list of Martin M. Eatock's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Eatock's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile